NYSE$ATR

AptarGroup Inc. · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Briefing

AptarGroup reported strong Q4 2023 operational results, driven by double-digit growth in proprietary drug delivery systems and strong growth in fragrance dispensing technologies.

AptarGroup's Q4 2023 results showed a 5% increase in reported sales and a 2% increase in core sales. Net income increased by 6% to $62 million. Adjusted earnings per share increased 27% to $1.21. The Pharma segment experienced over 20% core sales growth in proprietary dosing and dispensing systems.

  • Reported sales increased 5% and net income increased 6% to $62 million.
  • Core sales increased 2% and adjusted EBITDA increased 22% from the prior year to $179 million.
  • Reported earnings per share increased about 4% to $0.93 compared to $0.89 in the prior year, and adjusted earnings per share increased 27% to $1.21 compared to $0.95 in the prior year.
  • Margins continued to expand across all three segments over the prior year.

Headline financials

Total Revenue

$838M

Previous: $796M+5.3%
EPS (adj)

$1.21

Previous: $0.92+31.5%
Pharma Core Sales Growth

11.0%

Previous: 8.0%+37.5%
Beauty Core Sales Growth

-6.0%

Previous: 2.0%-400.0%
Closures Core Sales Growth

-4.0%

Previous: -4.0%+0.0%
Core Sales Growth

2.0%

Previous: 4.0%-50.0%
Capital Expenditures

$81.1M

Previous: $84.3M-3.7%
Net Income

$62.2M

Previous: $59.4M+4.8%
Operating Income

$84.2M

Previous: $85.2M-1.2%
Gross Profit

$312M

Previous: $276M+13.3%
Stock-Based Comp

$5.21M

Previous: $9M-42.1%

Revenue & EPS history

AptarGroup · Revenue · Quarterly

$838M

Q4 2023+5.3%vs Q4 2022
Beat estimate in 8 of 16 quarters(50%)
ActualEstimate

Revenue by segment

AptarGroup · $966M total across 3 segments · Q2 2025

  • Aptar Pharma
    $443M
  • Aptar Beauty
    $335M
  • Aptar Closures
    $189M

Forward guidance

Aptar expects earnings per share for Q1 2024, excluding restructuring expenses, changes in the fair value of equity investments and acquisition costs, to be in the range of $1.10 to $1.18.

Tailwinds

  • Demand for pharma’s proprietary drug delivery systems and elastomeric components for biologics to continue to grow.
  • Beauty and closures segments to benefit from a progressive recovery of the North American market.
  • Continued demand for fragrance dispensing technologies.
  • Remain focused on reducing SG&A as a percentage of sales.
  • Reducing fixed costs.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

+0.3%

Avg return

Earnings day

-0.1%

Avg return

5 days after

+1.2%

Avg return

30 days after

63%

43 / 68 earnings

Positive

+9.2%

Q4 2017

Best reaction

-9.0%

Q3 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2025
Q1 2026-3.3%-0.8%-6.4%
Q4 2025+8.3%+12.9%+6.5%
Q3 2025-9.0%-7.1%+0.3%
Q1 2025+2.3%+2.1%+6.8%
Q4 2024-8.5%-9.4%-2.3%
Q3 2024+0.8%+0.6%+2.3%
Q2 2024+1.7%+1.1%+4.4%
Q1 2024+2.4%+3.1%+5.8%
Q4 2023+5.4%+3.1%+8.6%
Q3 2023+0.1%-0.9%+4.2%
Q2 2023+3.2%+2.1%+6.3%
Q1 2023+2.4%+4.1%-1.4%
Q4 2022+5.7%+4.2%+0.3%
Q3 2022+2.1%-1.9%+6.9%
Q2 2022+1.6%+0.5%-1.5%
Q1 2022+3.4%+2.5%-2.0%
Q4 2021+3.3%+3.8%+2.7%
Q3 2021-3.6%+1.7%+1.0%
Q2 2021-6.3%-6.6%-2.3%
Q1 2021-0.2%+2.6%-2.5%
Q4 2020-7.7%-10.4%-2.7%
Q3 2020+1.6%+6.4%+13.3%
Q2 2020-3.0%-0.2%-0.6%
Q1 2020-3.6%-4.1%+1.2%
Q4 2019-2.6%-7.0%-19.6%
Q3 2019-7.1%-8.9%-6.0%
Q2 2019-5.0%-5.4%-1.3%
Q1 2019+1.3%+2.3%+2.0%
Q4 2018+1.5%+0.0%+2.2%
Q3 2018+1.8%+2.1%+2.0%
Q2 2018+8.6%+8.1%+9.6%
Q1 2018+0.3%+0.4%+1.0%
Q4 2017+9.2%+11.8%+9.6%
Q3 2017-0.6%-1.6%-2.5%
Q2 2017-6.5%-6.3%-6.4%
Q1 2017+1.2%+1.1%+6.3%
Q4 2016+1.7%+0.4%+4.4%
Q3 2016-4.3%-7.4%-0.3%
Q2 2016-1.9%-3.9%-1.6%
Q1 2016-3.1%
Q4 2015-2.8%
Q3 2015+2.4%
Q2 2015+8.3%
Q1 2015+2.4%
Q4 2014+1.8%
Q3 2014+2.0%
Q2 2014-3.5%
Q1 2014-0.1%
Q4 2013+1.9%
Q3 2013+0.2%
Q2 2013-2.1%
Q1 2013-2.0%
Q4 2012-0.8%
Q3 2012-3.5%
Q2 2012+2.6%
Q1 2012+0.9%
Q4 2011+0.1%
Q3 2011+5.8%
Q2 2011-5.0%
Q1 2010+2.2%
Q1 2011+2.3%
Q4 2008+1.5%
Q4 2010+1.5%
Q3 2009+2.9%
Q3 2010+2.9%
Q2 2010+0.5%
Q4 2009+0.5%
Q2 2009+0.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro